



(51) International Patent Classification:

C07D 307/80 (2006.01) *A61K 31/343* (2006.01)
A61P 9/00 (2006.01)

(21) International Application Number:

PCT/HU2011/000054

(22) International Filing Date:

10 June 2011 (10.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

P1000330 18 June 2010 (18.06.2010) HU

(71) Applicant (for all designated States except US):
SANOFI [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **FRIESZ, Antal** [HU/HU]; c/o Chinoin Gyógyszer és Vegyészeti Termékek Gyára Zrt., Iparjog, Tó u. 1-5., H-1045 Budapest (HU).(74) Agent: **SANOFI**; c/o János ÖRI and Dóra TEPFENHÁRT, Tó u. 1-5., H-1045 Budapest, (HU).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROCESS FOR THE PREPARATION OF DRONEDARONE



(57) Abstract: This invention relates to a process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)-propoxy]-benzoyl}-1-benzofuran-5-yl]-methane-sulfonamide of formula (I) and its pharmaceutically acceptable salts, according to one of the methylsulfonyl groups of the 2-n-butyl-3-[(di-n-butylamino-3-propoxy)-benzoyl]-5-bis-(methylsulfonyl)-benzofuran of formula (II) is selectively cleaved and if desired, the resulting compound of formula (I) is transformed into its salt.